TN2013000413A1 - Glycoside derivatives and their uses for the treatment of diabetes - Google Patents

Glycoside derivatives and their uses for the treatment of diabetes

Info

Publication number: TN2013000413A1
Authority: TN; Tunisia
Prior art keywords: diabetes; treatment; glycoside derivatives; present; provides
Prior art date: 2011-04-14

Application number

TNP2013000413A

Other languages

English (en)

Inventor

Gregory Raymond Bebernitz

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-14

Filing date

2013-10-11

Publication date

2015-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46028035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000413(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-10-11 Application filed by Novartis Ag filed Critical Novartis Ag

2015-03-30 Publication of TN2013000413A1 publication Critical patent/TN2013000413A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

TNP2013000413A 2011-04-14 2013-10-11 Glycoside derivatives and their uses for the treatment of diabetes TN2013000413A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161475476P	2011-04-14	2011-04-14
PCT/IB2012/051799 WO2012140597A1 (fr)	2011-04-14	2012-04-12	Dérivés de glycoside et leurs utilisations dans le traitement du diabète

Publications (1)

Publication Number	Publication Date
TN2013000413A1 true TN2013000413A1 (en)	2015-03-30

Family

ID=46028035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000413A TN2013000413A1 (en)	2011-04-14	2013-10-11	Glycoside derivatives and their uses for the treatment of diabetes

Country Status (26)

Country	Link
US (2)	US8614195B2 (fr)
EP (1)	EP2697217B1 (fr)
JP (1)	JP5908973B2 (fr)
KR (1)	KR20140027250A (fr)
CN (1)	CN103748090B (fr)
AP (1)	AP2013007179A0 (fr)
AR (1)	AR086086A1 (fr)
AU (1)	AU2012241427B2 (fr)
BR (1)	BR112013026257A2 (fr)
CA (1)	CA2832958A1 (fr)
CL (1)	CL2013002973A1 (fr)
CO (1)	CO6781541A2 (fr)
CR (1)	CR20130530A (fr)
CU (1)	CU20130139A7 (fr)
EA (1)	EA201391525A1 (fr)
ES (1)	ES2621007T3 (fr)
IL (1)	IL228771A0 (fr)
MA (1)	MA35032B1 (fr)
MX (1)	MX2013011927A (fr)
PE (1)	PE20141039A1 (fr)
PH (1)	PH12013502140A1 (fr)
SG (1)	SG194463A1 (fr)
TN (1)	TN2013000413A1 (fr)
TW (1)	TW201245219A (fr)
UY (1)	UY34018A (fr)
WO (1)	WO2012140597A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2714032B1 (fr) *	2011-06-01	2019-01-16	Green Cross Corporation	Nouveaux dérivés de diphénylméthane en tant qu'inhibiteurs de sglt2
PL2981269T3 (pl)	2013-04-04	2024-02-05	Boehringer Ingelheim Vetmedica Gmbh	Leczenie zaburzeń metabolicznych u zwierząt koniowatych
AU2014317663B2 (en) *	2013-09-09	2018-02-08	Youngene Therapeutics Co., Ltd.	C-aryl glucoside derivative, preparation method for same, and medical applications thereof
JP6450769B2 (ja)	2013-09-27	2019-01-09	サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅＬａｋｅＰｈａｒｍａＣｏ．，Ｌｔｄ．	グルコピラノシル誘導体及びその医薬品における使用
LT3862003T (lt)	2013-12-17	2023-12-27	Boehringer Ingelheim Vetmedica Gmbh	Sglt-2 inhibitorius, skirtas naudoti taikant medžagų apykaitos sutrikimo gydymą kačių šeimos gyvūnams
RS64355B1 (sr)	2014-01-23	2023-08-31	Boehringer Ingelheim Vetmedica Gmbh	Sglt2 inhibitori za lečenje metaboličkih poremećaja kod životinja iz roda kanin
NZ723781A (en) *	2014-04-01	2022-09-30	Boehringer Ingelheim Vetmedica Gmbh	Treatment of metabolic disorders in equine animals
HUE068152T2 (hu)	2014-09-25	2024-12-28	Boehringer Ingelheim Vetmedica Gmbh	SGLT2-gátlók és dopamin agonisták kombinációs kezelése anyagcserezavarok megelõzésére lófélékben
CN107995862B8 (zh)	2015-08-27	2021-12-03	勃林格殷格翰维特梅迪卡有限公司	包含sglt-2抑制剂之液态药物组合物
CN105294624B (zh) *	2015-11-16	2018-01-12	山东罗欣药业集团股份有限公司	一种达格列净的制备方法
CN108203432B (zh) *	2016-12-20	2021-03-02	宜昌东阳光长江药业股份有限公司	吡喃葡萄糖基衍生物及其在医药上的应用
AR111161A1 (es) *	2017-03-03	2019-06-12	Novartis Ag	Régimen de dosificación para el inhibidor sglt1/2 (licogliflozin)
WO2020242253A1 (fr) *	2019-05-30	2020-12-03	동아에스티 주식회사	Nouveau dérivé d'empagliflozine qui est un inhibiteur de sglt -2
WO2021121270A1 (fr) *	2019-12-19	2021-06-24	上海研健新药研发有限公司	Procédé de purification d'un inhibiteur des sglt et utilisation associée

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1020944C (zh)	1990-01-30	1993-05-26	阿图尔-费希尔股份公司费希尔厂	紧固件
KR100591585B1 (ko)	1999-08-31	2006-06-20	깃세이 야쿠힌 고교 가부시키가이샤	글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
US6627611B2 (en) *	2000-02-02	2003-09-30	Kotobuki Pharmaceutical Co Ltd	C-glycosides and preparation of thereof as antidiabetic agents
US7465712B2 (en)	2000-03-17	2008-12-16	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en)	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
PT1329456E (pt)	2000-09-29	2006-12-29	Kissei Pharmaceutical	Derivados de glucopiranosiloxibenzilbenzeno e composições medicinais que os contêm.
US6936590B2 (en)	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
EP1432720A1 (fr)	2001-09-05	2004-06-30	Bristol-Myers Squibb Company	Inhibiteurs de sglt2 contenant du glucoside de o-pyrazole et methode d'utilisation
TW200303742A (en)	2001-11-21	2003-09-16	Novartis Ag	Organic compounds
WO2004078163A2 (fr)	2003-02-28	2004-09-16	Transform Pharmaceuticals, Inc.	Compositions pharmaceutiques a base d'un co-cristal
DE10231370B4 (de)	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP2004137245A (ja)	2002-08-23	2004-05-13	Kissei Pharmaceut Co Ltd	ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US7202350B2 (en) *	2003-03-14	2007-04-10	Astellas Pharma Inc.	C-glycoside derivatives and salts thereof
AU2003902263A0 (en)	2003-05-12	2003-05-29	Fujisawa Pharmaceutical Co., Ltd.	Monosaccharide compounds
AR044399A1 (es)	2003-05-20	2005-09-14	Novartis Ag	Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen
EA010655B1 (ru)	2003-08-01	2008-10-30	Янссен Фармацевтика Н.В.	Замещенные индазол-о-глюкозиды
EP1660509B1 (fr)	2003-08-26	2009-02-04	Boehringer Ingelheim International GmbH	Pyrazoles glucopyranosyloxy, medicaments contenant ces composes, leur utilisation et leur procede de production
EP1721904A4 (fr)	2004-03-04	2010-07-14	Kissei Pharmaceutical	Derivie heterocyclique fondu; composition medicale contenant ce derive et usage medical
US7732596B2 (en)	2004-03-04	2010-06-08	Kissei Pharmaceutical Co., Ltd.	Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
DE102004028241B4 (de) *	2004-06-11	2007-09-13	Sanofi-Aventis Deutschland Gmbh	Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en)	2004-07-06	2008-07-01	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (de)	2004-07-17	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2574451A1 (fr)	2004-07-27	2006-02-02	Boehringer Ingelheim International Gmbh	Cyclenes substitues par d-glucopyranosyle-phenyle, medicaments contenant lesdits composes, leur utilisation et procede de production correspondant
WO2006018150A1 (fr)	2004-08-11	2006-02-23	Boehringer Ingelheim International Gmbh	Cycles a substitution d-xylopyranosyl-phenyle, medicaments contenant ces composes, leur utilisation, et leur procede de production
DE102004048388A1 (de)	2004-10-01	2006-04-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006054629A1 (fr)	2004-11-18	2006-05-26	Kissei Pharmaceutical Co., Ltd.	COMPOSÉS HÉTÉROCYCLIQUES AZOTÉS SUBSTITUÉS EN POSITION 1 ET AYANT UN GROUPE β-D-GLUCOPYRANOSYLE EN POSITION 3 ET MÉDICAMENTS CONTENANT CEUX-CI
AR053329A1 (es) *	2005-01-31	2007-05-02	Tanabe Seiyaku Co	Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
US20080027014A1 (en)	2006-07-28	2008-01-31	Tanabe Seiyaku Co., Ltd.	Novel SGLT inhibitors
TW200817424A (en)	2006-08-04	2008-04-16	Daiichi Sankyo Co Ltd	Benzylphenyl glucopyranoside derivatives
UY31651A1 (es) *	2008-02-13	2009-09-30		Nuevos derivados de fluoroglicósidos aromáticos, medicamentos que comprenden estos compuestos y uso de los mismos.
WO2010128152A1 (fr) *	2009-05-07	2010-11-11	Novartis Ag	C-glycosides hétérocycliques condensés pour le traitement du diabète
US8163704B2 (en) *	2009-10-20	2012-04-24	Novartis Ag	Glycoside derivatives and uses thereof

2012
- 2012-04-04 US US13/439,155 patent/US8614195B2/en active Active
- 2012-04-12 PH PH1/2013/502140A patent/PH12013502140A1/en unknown
- 2012-04-12 KR KR1020137029813A patent/KR20140027250A/ko not_active Withdrawn
- 2012-04-12 CN CN201280028536.3A patent/CN103748090B/zh not_active Expired - Fee Related
- 2012-04-12 AP AP2010307179A patent/AP2013007179A0/xx unknown
- 2012-04-12 BR BR112013026257A patent/BR112013026257A2/pt not_active IP Right Cessation
- 2012-04-12 PE PE2013002300A patent/PE20141039A1/es not_active Application Discontinuation
- 2012-04-12 JP JP2014504432A patent/JP5908973B2/ja not_active Expired - Fee Related
- 2012-04-12 WO PCT/IB2012/051799 patent/WO2012140597A1/fr not_active Ceased
- 2012-04-12 MA MA36319A patent/MA35032B1/fr unknown
- 2012-04-12 EP EP12719083.3A patent/EP2697217B1/fr active Active
- 2012-04-12 CA CA2832958A patent/CA2832958A1/fr not_active Abandoned
- 2012-04-12 EA EA201391525A patent/EA201391525A1/ru unknown
- 2012-04-12 ES ES12719083.3T patent/ES2621007T3/es active Active
- 2012-04-12 UY UY0001034018A patent/UY34018A/es not_active Application Discontinuation
- 2012-04-12 MX MX2013011927A patent/MX2013011927A/es not_active Application Discontinuation
- 2012-04-12 SG SG2013075908A patent/SG194463A1/en unknown
- 2012-04-12 AU AU2012241427A patent/AU2012241427B2/en not_active Ceased
- 2012-04-13 TW TW101113290A patent/TW201245219A/zh unknown
- 2012-04-13 AR ARP120101273A patent/AR086086A1/es unknown
- 2012-09-13 US US13/613,090 patent/US20130018005A1/en not_active Abandoned
2013
- 2013-10-07 IL IL228771A patent/IL228771A0/en unknown
- 2013-10-10 CO CO13241013A patent/CO6781541A2/es not_active Application Discontinuation
- 2013-10-11 TN TNP2013000413A patent/TN2013000413A1/fr unknown
- 2013-10-14 CU CU2013000139A patent/CU20130139A7/es unknown
- 2013-10-14 CR CR20130530A patent/CR20130530A/es unknown
- 2013-10-14 CL CL2013002973A patent/CL2013002973A1/es unknown

Also Published As

Publication number	Publication date
EP2697217B1 (fr)	2016-12-28
KR20140027250A (ko)	2014-03-06
ES2621007T3 (es)	2017-06-30
PH12013502140A1 (en)	2017-10-25
MX2013011927A (es)	2013-11-01
WO2012140597A1 (fr)	2012-10-18
US8614195B2 (en)	2013-12-24
SG194463A1 (en)	2013-12-30
IL228771A0 (en)	2013-12-31
AR086086A1 (es)	2013-11-20
AU2012241427A1 (en)	2013-10-31
AP2013007179A0 (en)	2013-10-31
CN103748090A (zh)	2014-04-23
JP2014511874A (ja)	2014-05-19
CA2832958A1 (fr)	2012-10-18
EP2697217A1 (fr)	2014-02-19
US20130018005A1 (en)	2013-01-17
UY34018A (es)	2012-11-30
TW201245219A (en)	2012-11-16
CR20130530A (es)	2014-02-04
MA35032B1 (fr)	2014-04-03
PE20141039A1 (es)	2014-08-30
BR112013026257A2 (pt)	2019-09-24
CU20130139A7 (es)	2014-01-29
JP5908973B2 (ja)	2016-04-26
CN103748090B (zh)	2016-09-14
CO6781541A2 (es)	2013-10-31
CL2013002973A1 (es)	2014-03-07
EA201391525A1 (ru)	2014-02-28
AU2012241427B2 (en)	2014-11-20
US20120264700A1 (en)	2012-10-18

Publication	Publication Date	Title
TN2013000413A1 (en)	2015-03-30	Glycoside derivatives and their uses for the treatment of diabetes
TN2014000030A1 (en)	2015-07-01	Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
PH12018501807A1 (en)	2019-03-25	Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
IN2015DN00185A (fr)	2015-06-12
PH12014502462A1 (en)	2014-12-22	Complement pathway modulators and uses thereof
PH12016500072B1 (en)	2016-04-18	Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
TN2013000275A1 (en)	2014-11-10	Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
WO2014002051A3 (fr)	2014-03-20	Modulateurs de la voie du complément et leurs utilisations
MX2016000675A (es)	2016-05-10	Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
WO2014002058A3 (fr)	2014-03-20	Modulateurs de la voie du complément et utilisations de ceux-ci
MX2015008975A (es)	2015-09-29	Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
MX2015016344A (es)	2016-03-01	Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MY184008A (en)	2021-03-17	Aryl pyridine as aldosterone synthase inhibitors
MX2015016421A (es)	2016-03-03	Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2011012199A (es)	2011-12-08	Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
MX2013011926A (es)	2013-11-01	Derivados de glicosido y usos de los mismos.
MX2016006667A (es)	2016-07-26	Derivados de pirrolo-pirrolona y su uso como inhibidores.
TN2014000060A1 (en)	2015-07-01	Benzothiazolone compound
TN2012000617A1 (en)	2014-04-01	2,3,5-trisubstituted thiophene compounds and uses thereof
MY169038A (en)	2019-02-07	Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
PH12013500155A1 (en)	2013-02-18	2,3,5-trisubstituted thiophene compounds and uses thereof
TN2011000573A1 (en)	2013-05-24	Aryl pyridine as aldosterone synthase inhibitors